(Q40389484)

English

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells (English)

1 reference

Europe PubMed Central

20 September 2017

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

3

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

20 September 2017

5

object named as

Zeev Estrov

1 reference

Europe PubMed Central

20 September 2017

Srdan Verstovsek

1

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

20 September 2017

Jorge Eduardo Cortes

11

object named as

Jorge Cortes

1 reference

Europe PubMed Central

20 September 2017

12

object named as

Francis Giles

1 reference

Europe PubMed Central

20 September 2017

10

object named as

Margaret Dugan

1 reference

Europe PubMed Central

20 September 2017

9

object named as

Leila Alland

1 reference

Europe PubMed Central

20 September 2017

Mirna Golemovic

2

object named as

Mirna Golemovic

1 reference

Europe PubMed Central

20 September 2017

Ralph B. Arlinghaus

8

object named as

Ralph B Arlinghaus

1 reference

Europe PubMed Central

20 September 2017

author name string

Tashi Manshouri

4

1 reference

Europe PubMed Central

20 September 2017

Paul Manley

6

1 reference

Europe PubMed Central

20 September 2017

Tong Sun

7

1 reference

Europe PubMed Central

20 September 2017

Miloslav Beran

13

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

104

1 reference

Europe PubMed Central

20 September 2017

6

1 reference

Europe PubMed Central

20 September 2017

1230-1236

1 reference

Europe PubMed Central

20 September 2017

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to imatinib (Glivec): update on clinical mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21299

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21299

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40389484&oldid=2151992386"